Shanghai Argo Biopharmaceutical Co., Ltd.

Argo Biopharma is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to the research, development, and production of next-generation RNA interference (RNAi) therapeutics. Established in April 2021, the company's mission is to advance RNA science and develop transformative medicines that meaningfully improve the lives of people living with chronic diseases globally.

The company specializes in siRNA drug discovery and development, leveraging its proprietary RADS™ (RNA molecules with superior Activity, Durability, and Safety) platform technology. Argo Biopharma's robust and diverse pipeline includes RNAi drug candidates targeting a broad range of indications, such as cardiovascular diseases, viral infections, metabolic conditions, rare diseases, central nervous system (CNS) disorders, and hematological diseases. As of early 2026, the company has seven RNAi candidates in clinical development, including BW-20805 for Hereditary Angioedema (HAE), BW-20829 for elevated Lp(a), and BW-40202 for paroxysmal nocturnal hemoglobinuria (PNH).

Co-founded by Dongxu Shu, who serves as CEO and Chairman of the Board, Argo Biopharma has quickly gained market recognition. In March 2026, the company appointed Gena Wang as Chief Financial Officer and Chief Strategy Officer. Argo Biopharma has also forged significant strategic collaborations with Novartis, including licensing deals in January 2024 and September 2025 for multiple cardiovascular assets, with potential milestone payments totaling billions of dollars. The company was recognized on Fast Company's Annual List of the World's Most Innovative Companies of 2026.